CXCL10 and neoplasm: Previous studies have established that TIME featuring CD8+ T cell infiltration without PD‐L1 expression exhibits reduced sensitivity to anti‐PD‐1/PD‐L1 immunotherapy.[42] In the combination therapy group, the release of large amounts of tumor antigens from tumor cells killed by anti‐PD‐1 therapy, as well as the increased secretion of CXCL10 induced by Yoda 1, will recruit more CD8+ T cells and release more tumor antigens, thus further achieving a cascade response in the anti‐tumor immune cycle.